Antiemetics Market Size, Share, Competitive Landscape and Trend Analysis Report, by Drug Type, by Application, by Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2022-2031

Antiemetics Market Research, 2031

The global antiemetics market was valued at $2.3 billion in 2021, and is projected to reach $4.1 billion by 2031, growing at a CAGR of 6.1% from 2022 to 2031. The drugs or medications which helps to prevent and treat conditions such as nausea, and vomiting are referred as antiemetic drugs. Emesis can be caused due to various ailments including vertigo and motion sickness. Also chemotherapies are associated with the side effects such as nausea and vomiting which can be treated or prevented with these antiemetics. Furthermore, these antiemetic drugs belongs to different class such as serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists and others and have wide applications in the healthcare sector. These drugs can also be used to treat vomiting caused by several medical conditions, including gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and others.

According to Cancer Statistics by the National Cancer Institute, in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people died from the disease, which highlights the higher utilization of the chemotherapy treatment. Chemotherapy-induced nausea and vomiting is the most severe symptoms for cancer patients receiving the chemotherapy which can further lead to metabolic disorders, dehydration, nutritional depletion and esophageal tears, and can affect the quality of life and interfere with treatment schedules. Thus, this highlights the need for the antiemetic treatment for the patient, leading to the expansion of the market. For instance, the most commonly used treatment for chemotherapy-induced nausea and vomiting is a combination of serotonin (5-HT3) receptor antagonists, a steroid (dexamethasone), and a neurokinin-1 (NK1) receptor antagonist (aprepitant).

Furthermore, nausea and vomiting during the pregnancy is a common condition which is known as “morning sickness”. Nausea and vomiting of pregnancy usually doesn't harm the fetus, but it can affect normal everyday activities. American Academy of Family Physicians (AAFP) states that, nausea and vomiting of pregnancy affects nearly 75% of pregnant women and about 1% of women develop hyper-emesis gravidarum, which may result in adverse outcomes for the mother and fetus. In some cases, morning sickness lasts much longer, and antiemetic drugs are extremely helpful in treating such conditions. Thus, this highlights the demand for the antiemetics during the pregnancy propelling the growth of the antiemetics market.

Also the rise in prevalence of the vertigo and vestibular neuritis which causes symptoms as dizziness, balance problems, nausea and vomiting, will contribute to the rise in demand of the antiemetic drugs. Also, the rise in the prevalence of the gastroenteritis, food poisoning, and vomiting and nausea associated diseases boost the antiemetics market growth.

In addition, the primary driving factors for the market growth include the patent expiration of various drugs, launching of more cost-effective generic substitutes, and rise in the investments by the key market players in manufacturing of the antiemetic drug molecules.

Furthermore, less knowledge regarding the appropriate dosage, strength and usage are expected to hamper the market growth. However, increase in healthcare expenditure and rising research and development activities, will provide large antiemetics market opportunity for investment to the market players during the antiemetics market forecast.

The antiemetics market is segmented on the basis of drug type, application, distribution channel and region. On the basis of drug type, the market is bifurcated into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and other drug type. On the basis of application, the market is segmented into chemotherapy, post operative surgery, pregnancy and gastroenteritis and other applications. On the basis of distribution channel, the market is categorized into retail pharmacies, hospital pharmacies and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

By drug type, the serotonin receptor antagonists segment dominated the antiemetics market size in 2021, and is estimated to be the fastest growing segment, with a high CAGR of 7.1% owing to the rise in the demand for Ondansetron and Gravisetron for preventing vomiting and nausea mostly after surgical procedures.

Depending on the application, the chemotherapy segment dominated the antiemetics market size in 2021, due to the rise in the cancer cases and subsequent rise in the chemotherapies for the treatment whereas the post operative surgery segment is estimated to grow with a CAGR of 6.7% in the forecasted period due rise in the number of surgeries around the globe due to the recent advancements and developments in the surgical procedures which causes the shift of the population towards surgeries as a treatment option.

Depending on distribution channel, the retail pharmacies segment owned the largest share of the antiemetics market share in 2021, whereas the online pharmacies is expected to grow at the highest CAGR of 7.7% during the forecast period due to the rise in the adoption of the smart phones, heavy discounts and offers, doorstep delivery and other advantages of the online pharmacies.

Region wise, North America acquired a major antiemetics market share in the year 2021, and registered the growth at a CAGR of 5.1%. However, Asia-Pacific is expected to witness the highest growth rate for the antiemetics market throughout the forecast period with a CAGR of 7.8%. The major factors that drive the growth of the antiemetics market is the elevating healthcare demand for highly potent drug, and adoption of radiation therapy for the cancer treatment. Moreover, availability of excessive raw material in this region and also, the rise in market players investing in research and development are leveraging the antiemetics industry.

Some of the major companies that operate in the global antiemetics industry are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy’s Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiemetics market analysis from 2021 to 2031 to identify the prevailing antiemetics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the antiemetics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global antiemetics market trends, key players, market segments, application areas, and market growth strategies.

  Antiemetics Market Report Highlights

Aspects	Details
Market Size By 2031	USD 4.1 billion
Growth Rate	CAGR of 6.1%
Forecast period	2021 - 2031
Report Pages	260
By Drug Type	Antihistamines Serotonin Receptor Antagonists Dopamine Receptor Antagonists Neurokinin Receptor Antagonists Anticholinergics Other Drug Types
By Distribution Channel	Retail Pharmacies Hospital Pharmacies Online Pharmacies
By Application	Chemotherapy Post Operative Surgery Pregnancy and Gatroenteritis Other Applications
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, UK, Italy, Spain, Rest Of Europe) Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest Of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest Of LAMEA)
Key Market Players	Johnson & Johnson, Eisai Co. Ltd, Novartis AG, GlaxoSmithKline Plc, Dr. Reddy’s Laboratories Ltd, Merck & Co. Inc, F. Hoffmann-La Roche Ltd, Teva Pharmaceuticals, Cipla, Pfizer Inc

Analyst Review

This section provides opinions of the top-level CXOs operating in the global antiemetics market. According to the insights of the CXOs, the global antiemetics market is expected to exhibit high growth potential attributable to factors such as rise in in R&D activities in pharmaceutical industry for manufacturing of the antiemetic medicines; increase in prevalence of cancer and gastroenteritis diseases and surge in number advancements in the diagnosis and treatment. Furthermore, the antiemetics market has gained interest of many pharmaceutical companies, owing to surge in demand for the medications due to rise in the patient pool in the regions such as Asia-Pacific and LAMEA. Moreover, increase in number of geriatric patients, who are highly prone to viral and bacterial infections due to poor immunity, notably contributes toward the growth of the market.

 

The CXOs further added that North America is expected to witness the highest growth, in terms of revenue, rise in incidences of chronic illness, high adoption rate, high prevalence of unmet medical needs, robust R&D infrastructure for life science researches, presence of key players, and advancements in healthcare investments and Asia-Pacific is expected to register highest growth during the forecast period, due to the continuous government support for pharmaceutical and R&D, increase in public–private investments, and rise in number of research activities in the healthcare sector for improved and efficient treatment. In addition, abundance of pipeline products is anticipated to drive the market growth. In addition, Asia-Pacific possesses high potential for the growth of antiemetics market due to the presence of high population base and untapped market opportunities.

Author Name(s) : Mansi Pardeshi| Madhuvanti Balkrishna Divekar | Roshan Deshmukh

Related Tags

• Chemotherapy
• Oncology
• Cancer Drugs
• Api
• Medical Tourism

^*Terms and Conditions Apply